Market capitalization | $1.61b |
Enterprise Value | $1.10b |
P/E (TTM) P/E ratio | 93.71 |
EV/FCF (TTM) EV/FCF | 48.33 |
EV/Sales (TTM) EV/Sales | 4.20 |
P/S ratio (TTM) P/S ratio | 6.15 |
P/B ratio (TTM) P/B ratio | 2.35 |
Revenue growth (TTM) Revenue growth | -27.79% |
Revenue (TTM) Revenue | $260.81m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
6 Analysts have issued a Dynavax Technologies Corporation forecast:
6 Analysts have issued a Dynavax Technologies Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 261 261 |
28%
28%
|
|
Gross Profit | 216 216 |
11%
11%
|
|
EBITDA | 0.50 0.50 |
99%
99%
|
EBIT (Operating Income) EBIT | -7.44 -7.44 |
120%
120%
|
Net Profit | 20 20 |
66%
66%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
Head office | United States |
CEO | Ryan Spencer |
Employees | 408 |
Founded | 1996 |
Website | www.dynavax.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.